NCT05746598

Unknown

Effect of Genetic and Epigenetic Factors on the Clinical Res...

Ain Shams University Source

Compare

Other study identifiers

Sponsor study identifier

NSCLC-Genetics

Study Type

observational

Estimated enrollment

178

Locations

1 country

Sites

1

Timeline

Study Start

July 1, 2020

Actual (reported)

Primary Completion

March 1, 2023

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

April 1, 2023

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Brief Summary

Lung cancer is the leading cause of death worldwide, with non-small-cell lung cancer (NSCLC) being the most common histotype according to the global cancer observatory 2022. A variety of therapeutic options for advanced/metastatic non-oncogene-addicted NSCLC have recently been approved based on their impact on patient outcomes in terms of survival and safety profile. Current guidelines advocate for personalized treatment options based on molecular and immunologic characteristics, which drives the physician's decision toward tailored oncology. In the last two to three decades, hundreds of cancer biological prognostic markers for non-small cell lung cancer have been proposed. Although they have shown a potential in this ﬁeld, validation studies are still required and, to date, there is in suﬃcient evidence to recommend the routine clinical use of any of these putative biomarkers. Therefore, the discovery of robust prognostic and/or predictive biomarkers in patients with non-small cell lung cancer is imperative for advancing treatment strategies for the disease and improving patient care.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Estimated enrollment: 178 participants
Study completion date: April 1, 2023
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
July 1, 2020
Actual (reported)
First Submitted
February 8, 2023
Actual (reported)
First Posted
February 28, 2023
Actual (reported)
Primary Completion
March 1, 2023
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
April 1, 2023
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated: February 28, 2023
Status Verified: February 2023
Last Update Submitted: February 16, 2023

Conditions

Non Small Cell Lung Cancer Nephropathy Cardiotoxicity

Keywords

Non-small cell lung CancerNephropathyCardiotoxicityGene polymorphismCisplatin

Outcome Measures

Primary Outcomes (1)

Nephrotoxicity
Change in Creatinine Clearance
6 months

Secondary Outcomes (3)

Blood urea nitrogen
6 months
Serum creatinine
6 month
Cardiotoxicity
6 months

Study Arms (2)

1

NSCLC patients Who developed Toxicity to Chemotherapeutic agents

Drug: Cisplatin injection

2

NSCLC patients Who did not developToxicity to Chemotherapeutic agents

Drug: Cisplatin injection

Interventions

Cisplatin injectionDrug

Cisplatin 75mg/m2

12

Eligibility Criteria

Age18 Years - 80 Years

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

• NSCLC cancer patients treated with Cisplatin-containing chemotherapy.

You may qualify if:

NSCLC cancer patients treated with Cisplatin-containing chemotherapy.

Sponsors & Collaborators

Misr International University
Othercollaborator
Ain Shams University
Otherlead

Study Sites (1)

Ain Shams University

Cairo, 11315, Egypt

RECRUITING

Neven Sarhan, PhDCONTACT+201021944422 sarhanneven@gmail.com

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral Blood Samples

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell LungKidney DiseasesCardiotoxicity

Interventions

Cisplatin

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesUrologic Diseases

Central Study Contacts

Neven Sarhan, PhD

CONTACT

+201021944422 sarhanneven@gmail.com

Mona Schaalan, PhD

CONTACT

mona.schaalan@miuegypt.edu.eg

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Lecturer

Study Record Dates

First Submitted

February 8, 2023

First Posted

February 28, 2023

Study Start

July 1, 2020

Actual (reported)

Primary Completion

March 1, 2023

Estimated (date passed)

NCT06358599

The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy

Completed

NCT04444869

Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer

Phase 2Recruiting

NCT06880289

Chemo-Radiotherapy Boost Treatment Guided by Perfusion MRI on Hypoxic Zones in Head and Neck Cancer

Phase 2Active Not Recruiting

NCT03772028

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Phase 3Active Not Recruiting

NCT03909776

Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma

Not ApplicableCompleted

NCT03275857

Cisplatin in Castration Resistant Prostate Cancer

Early Phase 1Completed

Measurable disease.

Age of 18 years to 80 years.

You may not qualify if:

Non-small cell lung cancer patients who had undergone radiotherapy or chemotherapy.
Pregnant and lactating females.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaliplatin.

Contact the study team to confirm eligibility.

Female Urogenital Diseases

Female Urogenital Diseases and Pregnancy Complications

Urogenital Diseases

Male Urogenital Diseases

Heart Diseases

Cardiovascular Diseases

Pathologic Processes

Pathological Conditions, Signs and Symptoms

Drug-Related Side Effects and Adverse Reactions

Chemically-Induced Disorders

Radiation Injuries

Wounds and Injuries

Intervention Hierarchy (Ancestors)

Chlorine CompoundsInorganic ChemicalsNitrogen CompoundsPlatinum Compounds

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

April 1, 2023

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated

February 28, 2023

Record last verified: 2023-02

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT05746598
Data provider: ClinicalTrials.gov
Source updated: 2023-02-28
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:28:57 UTC

Locations

EG(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (2)

1

2

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations